|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:temple
|
|
gptkbp:activities
|
PD-L1 inhibitor
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
radiation therapy
chemotherapy
|
|
gptkbp:clinical_trial
|
gptkb:CASPIAN_trial
gptkb:PACIFIC_trial
oncology
Phase III
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:formulation
|
solution for infusion
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Imfinzi
|
|
gptkbp:indication
|
unresectable stage III non-small cell lung cancer
relapsed or refractory small cell lung cancer
|
|
gptkbp:ingredients
|
gptkb:durvalumab
|
|
gptkbp:invention
|
gptkb:temple
|
|
gptkbp:is_used_for
|
treatment of non-small cell lung cancer
treatment of small cell lung cancer
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
gptkb:brand
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
gptkb:vaccine
biologics
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
hepatitis
diarrhea
rash
immune-related adverse events
thrombocytopenia
infusion-related reactions
neuropathy
pneumonitis
hypersensitivity reactions
colitis
endocrinopathies
increased liver enzymes
immune-mediated reactions
myocarditis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:PD-1
gptkb:PD-L1
|